Search Results - C.C. Coombs

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL... by J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill, D. Wang, N. C. Ku, A. Guntur, S. Shahda, C. C. Leow, P. Ghia, A. R. Mato

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1... by L. E. Roeker, A. R. Mato, J. R. Brown, C. C. Coombs, N. N. Shah, W. G. Wierda, M. R. Patel, K. L. Lewis, M. Balbas, J. Zhao, N. C. Ku, J. F. Kherani, D. E. Tsai, B. Nair, C. Y. Cheah

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    C059 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATE... by P. Ghia, D. Rossi, E. Ferrant, F. De La Cruz Vicente, D. Maruyama, V. Banerji, P. Cobb, S. Namburi, R. Greil, A. Loubert, K. Creel, L.M. Hess, N. Payakachat, A.S. Ruppert, D. Wang, P. Abada, C.C. Leow, M. Hill, C.C. Coombs, P. Barr, J.P. Sharman

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  4. 4

    P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS by A. R. Mato, B. S. Manzoor, C. C. Coombs, N. Lamanna, H. H. Tuncer, J. R. Brown, L. E. Roeker, M. Shadman, J. N. Allan, C. Ujjani, B. Eichhorst, L. Leslie, I. Fleury, H. Alhasani, J. Rhodes, B. T. Hill, P. M. Barr, A. Skarbnik, M. S. Davids, R. Bannerji, M. Fuldeore, F. Lansigan, A. Schuh, L. Pearson, C. P. Fox, I. Pivneva, L. Popadic, A. Guerin, T. A. Eyre

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by A. R. Mato, J. M. Pagel, C. C. Coombs, N. N. Shah, N. Lamanna, T. Munir, E. Lech-Maranda, T. A. Eyre, J. A. Woyach, W. G. Wierda, C. Y. Cheah, J. B. Cohen, L. E. Roeker, M. R. Patel, B. Fakhri, M. A. Barve, C. Tam, D. Lewis, J. N. Gerson, A. J. Alencar, C. Ujjani, I. Flinn, S. Sundaram, S. Ma, D. Jagadeesh, J. Rhodes, J. Taylor, O. Abdel-Wahab, P. Ghia, S. J. Schuster, D. Wang, B. Nair, E. Zhu, D. E. Tsai, M. S. Davids, J. R. Brown, W. Jurczak

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  6. 6

    P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by T. A. Eyre, M. L. Wang, N. N. Shah, A. J. Alencar, J. N. Gerson, M. R. Patel, B. Fakhri, E. Vandenberghe, W. Jurczak, X. N. Tan, K. L. Lewis, T. Fenske, Y. Wang, C. C. Coombs, I. Flinn, D. Lewis, S. Le Gouill, M. Gandhi, C. Chay, M. L. Palomba, J. A. Woyach, J. M. Pagel, N. Lamanna, J. P. Sharman, D. J. Andorsky, J. B. Cohen, M. A. Barve, P. Ghia, M. Yin, P. L. Zinzani, C. Ujjani, Y. Koh, K. Izutsu, E. Lech-Maranda, J. Kherani, C. Tam, S. Sundaram, B. Nair, D. E. Tsai, M. Balbas, A. R. Mato, C. Y. Cheah

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: